Examines phenylephrine's impact on inflammatory cytokines in macrophages, suggesting clinical relevance.
Background Phenylephrine (PE) acts as a sympathomimetic vasoconstrictor frequently utilized to alleviate nasal blockage via the activation of α-1-adrenergic receptors. This study primarily sought to investigate the drug’s potential to influence immune system responses. Methods: The effect of phenylephrine was analyzed by comparing cytokine production levels in LPS-stimulated and unstimulated J774.1 macrophages. The changes in concentrations of IL-6, TNF-α, IL-12p40, and GM-CSF induced by phenylephrine were measured by ELISA. Results: PE exhibited no intrinsic pro-inflammatory activity, as basal levels of TNF-α, IL-12p40, IL-6, and GM-CSF remained at or near detection limits in PE-only groups. In LPS-stimulated cultures, PE significantly attenuated the inflammatory response across multiple pathways, though the inhibitory patterns varied by cytokine. PE induced a robust, non-dose-dependent inhibition, reducing levels by 40–45% across all concentrations (P < 0.05). A significant dose-dependent suppression was observed, with the maximal dose (10 µg/mL) reducing levels from 9,258 pg/mL to 5,802 pg/mL (P < 0.05). Inhibition followed a non-monotonic trend; concentrations of 1 and 10 µg/mL significantly lowered IL-6 (P < 0.05), while the intermediate 5 µg/mL dose yielded no significant effect. PE mediated modulation was restricted, with significant inhibition occurring only at the highest concentration (10 µg/mL; P < 0.05). Conclusion: The results indicate that phenylephrine influences inflammatory cytokine production and may have potential clinical relevance regarding immune responses and inflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Aydemir et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: